hominis . DC159a MICs were < 0.5 µg/ml for all Mycoplasma species and < 4 µg/ml for 8 ureaplasmas. DC-159a was the most active fluoroquinolone tested against M. parvum isolates were known to be resistant to tetracycline (MICs > 8 µg/ml). One isolate 16 of U. parvum was known to be resistant to fluoroquinolones (levofloxacin MIC = 16 17 µg/ml) (2).
organisms.
9
Fluoroquinolones are useful treatment options for mycoplasmal and ureaplasmal 10 infections because they have the advantages of being well tolerated in oral 11 formulations; they have long half lives allowing once daily dosage; they possess 12 bactericidal activity; they are not affected by resistance mechanisms that affect other 13 drug classes such as tetracyclines and macrolides; and documented in vitro resistance 14 is uncommon (3, 8, 9, 11 parvum isolates were known to be resistant to tetracycline (MICs > 8 µg/ml). One isolate 16 of U. parvum was known to be resistant to fluoroquinolones (levofloxacin MIC = 16 17 µg/ml) (2).
18
A microbroth dilution method was performed as described previously to Mycoplasma species at concentrations < 0.5 µg/ml. All Ureaplasma isolates were 13 inhibited at concentrations < 4 µg/ml, including the U. parvum previously known to be 
19
Ten M. pneumoniae isolates were tested further to determine MBCs for DC-159a 20 in comparison to moxifloxacin and levofloxacin. MBC testing was performed directly 21 from microtiter plates used to determine MICs as previously described (9, 10).
22
Bactericidal effect was identified when the MBC was within 1 -4 times the MIC value. 
